PAIN+ CPN

Corbett M, South E, Harden M, et al. Brain and spinal stimulation therapies for phantom limb pain: a systematic review. Health Technol Assess. 2018 Nov;22(62):1-94. doi: 10.3310/hta22620. (Systematic review)
Abstract

BACKGROUND: Although many treatments exist for phantom limb pain (PLP), the evidence supporting them is limited and there are no guidelines for PLP management. Brain and spinal cord neurostimulation therapies are targeted at patients with chronic PLP but have yet to be systematically reviewed.

OBJECTIVE: To determine which types of brain and spinal stimulation therapy appear to be the best for treating chronic PLP.

DESIGN: Systematic reviews of effectiveness and epidemiology studies, and a survey of NHS practice.

POPULATION: All patients with PLP.

INTERVENTIONS: Invasive interventions - deep brain stimulation (DBS), motor cortex stimulation (MCS), spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation. Non-invasive interventions - repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).

MAIN OUTCOME MEASURES: Phantom limb pain and quality of life.

DATA SOURCES: Twelve databases (including MEDLINE and EMBASE) and clinical trial registries were searched in May 2017, with no date limits applied.

REVIEW METHODS: Two reviewers screened titles and abstracts and full texts. Data extraction and quality assessments were undertaken by one reviewer and checked by another. A questionnaire was distributed to clinicians via established e-mail lists of two relevant clinical societies. All results were presented narratively with accompanying tables.

RESULTS: Seven randomised controlled trials (RCTs), 30 non-comparative group studies, 18 case reports and 21 epidemiology studies were included. Results from a good-quality RCT suggested short-term benefits of rTMS in reducing PLP, but not in reducing anxiety or depression. Small randomised trials of tDCS suggested the possibility of modest, short-term reductions in PLP. No RCTs of invasive therapies were identified. Results from small, non-comparative group studies suggested that, although many patients benefited from short-term pain reduction, far fewer maintained their benefits. Most studies had important methodological or reporting limitations and few studies reported quality-of-life data. The evidence on prognostic factors for the development of chronic PLP from the longitudinal studies also had important limitations. The results from these studies suggested that pre-amputation pain and early PLP intensity are good predictors of chronic PLP. Results from the cross-sectional studies suggested that the proportion of patients with severe chronic PLP is between around 30% and 40% of the chronic PLP population, and that around one-quarter of chronic PLP patients find their PLP to be either moderately or severely limiting or bothersome. There were 37 responses to the questionnaire distributed to clinicians. SCS and DRG stimulation are frequently used in the NHS but the prevalence of use of DBS and MCS was low. Most responders considered SCS and DRG stimulation to be at least sometimes effective. Neurosurgeons had mixed views on DBS, but most considered MCS to rarely be effective. Most clinicians thought that a randomised trial design could be successfully used to study neurostimulation therapies.

LIMITATION: There was a lack of robust research studies.

CONCLUSIONS: Currently available studies of the efficacy, effectiveness and safety of neurostimulation treatments do not provide robust, reliable results. Therefore, it is uncertain which treatments are best for chronic PLP.

FUTURE WORK: Randomised crossover trials, randomised N-of-1 trials and prospective registry trials are viable study designs for future research.

STUDY REGISTRATION: The study is registered as PROSPERO CRD42017065387.

FUNDING: The National Institute for Health Research Health Technology Assessment programme.

Ratings
Discipline Area Score
Physician 5 / 7
Rehab Clinician (OT/PT) 5 / 7
Comments from MORE raters

Physician rater

The epidemiolgical evidence is useful for indicating the high prevalence of phantom limb pain and factors that increase the likelihood of developing PLP. The studies on treatment provide little useful information to the clinician, except for short term benefit for rTMS and direct current stimulation. Definitive trials, even n-of-1 studies are badly needed, that include longer term follow-up.

Physician rater

In my practice, I have amputee people. Many of them have Phantom Limb Pain. In my country, there are only a few institutions with access to Brain or Spinal stimulation. I know this is a new tool and this will change the pain management in these patients.

Rehab Clinician (OT/PT) rater

As physiotherapist, I find these results are out of normal practice. However, they are needed to support decisions of other treatments. As a researcher, I find the study is highly interested.

Rehab Clinician (OT/PT) rater

As a pain physician, I find this article extremely useful! I recommend it to my colleagues.

Rehab Clinician (OT/PT) rater

'Seven randomised controlled trials (RCTs), 30 non-comparative group studies, 18 case reports and 21 epidemiology studies were included'. The paucity of high grade evidence was a surprise given the distressing and relatively common prevalence of the condition. It was interesting to see the key determinants of PLP appeared to be pre-amputation pain and early post-amputation onset pain. Presumably intensity may be a factor in both? Given current pain theory associated with central and peripheral sensitisation, it might appear more fruitful to direct mitigation of PLP at the pre-amputation state?
Comments from PAIN+ CPN subscribers

No subscriber has commented on this article yet.